Compare CDRE & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDRE | BSX |
|---|---|---|
| Founded | 2012 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 137.8B |
| IPO Year | 2021 | 1992 |
| Metric | CDRE | BSX |
|---|---|---|
| Price | $40.81 | $94.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 17 |
| Target Price | $34.50 | ★ $125.88 |
| AVG Volume (30 Days) | 203.3K | ★ 9.3M |
| Earning Date | 11-04-2025 | 02-04-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | 33.82 | ★ 54.68 |
| EPS | 1.11 | ★ 1.87 |
| Revenue | $619,068,000.00 | ★ $19,349,000,000.00 |
| Revenue This Year | $12.51 | $21.05 |
| Revenue Next Year | $8.21 | $11.44 |
| P/E Ratio | ★ $37.11 | $50.65 |
| Revenue Growth | 19.94 | ★ 21.61 |
| 52 Week Low | $27.07 | $85.98 |
| 52 Week High | $46.64 | $109.50 |
| Indicator | CDRE | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 42.76 | 42.88 |
| Support Level | $41.40 | $95.55 |
| Resistance Level | $42.46 | $96.33 |
| Average True Range (ATR) | 1.26 | 1.45 |
| MACD | -0.17 | 0.23 |
| Stochastic Oscillator | 13.15 | 62.92 |
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.